Market closed· · CAD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Not for distribution by US newswire or in United States NESS-ZIONA, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. ("Vaxil" or the "Company") (TSX VENTURE: VXL) is pleased to announce that the Company, further to it's news release from October 29, 2025, that it has revised the terms of its previously announced offering and now intends to complete a non-brokered private placement on a commercially reasonable efforts basis (the "Offering") of up to 3,111,111 units ("Units") of the Compan
Not for distribution by US newswire or in United States NESS-ZIONA, ISRAEL, Oct. 29, 2025 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), is pleased to announce that the Company intends to complete a non-brokered private placement on a commercially reasonable efforts basis (the "Offering") of up to 2,456,140 units ("Units") of the Company at a price of $0.1425 per Unit to raise gross proceeds of up to $350,000. Each Unit will consist of one common share of the C
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.